Mediators of Inflammation

Airway Inflammatory/Immune Responses in COPD and Cystic Fibrosis


Status
Published

1University of Torino, Torino, Italy

2Paris Descartes University, Paris, France

3University of Alabama at Birmingham, Birmingham, USA

4Royal College of Surgeons in Ireland, Dublin, Ireland


Airway Inflammatory/Immune Responses in COPD and Cystic Fibrosis

Description

Cystic fibrosis (CF) is a genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and remains one of the most common fatal hereditary disorders worldwide. Although CF is a complex multiorgan disease, morbidity and mortality are mainly determined by progressive chronic obstructive lung disease.

COPD is a major and increasing global health problem. The disease is caused by both genetic and environmental factors, and cigarette smoking is the main risk factor.

Although the pathogenesis and the pathophysiology of these diseases are different, they share key phenotypical features, including reduced mucociliary clearance, small airways mucus obstruction, goblet cell metaplasia and mucus hypersecretion, chronic neutrophilic airway inflammation, exacerbated innate and adaptive immune responses in airways, and chronic/recurrent bacterial infections. In both diseases, a persistent high-intensity inflammation, driven by continuous neutrophil recruitment, leads to permanent structural damage of the airways and impaired lung function. Furthermore, both patients with CF and COPD also suffer from systemic inflammation.

Several defective inflammatory responses have been linked to CFTR deficiency including innate and acquired immunity dysregulation, cell membrane lipid abnormalities, and various transcription factor signaling defects. Interestingly, cigarette smoke has also been implicated in reduced CFTR expression and function, suggesting that common mechanisms may contribute to the chronic nonresolving inflammation in both CF and COPD. These mechanisms however are still poorly defined. An improved understanding of the common mechanisms and/or pathways that can be affected by both CFTR mutations and environmental insults involved in COPD should provide a road map for potential therapeutic interventions in future COPD therapies.

This special issue will focus on airway inflammation, structural abnormalities, and immune responses in CF and COPD. We invite investigators to contribute original research articles as well as review articles focusing on similarities and differences between inflammatory/immune responses in CF and COPD, potential mechanistic links, and common therapeutic targets.

Potential topics include but are not limited to the following:

  • Investigations into evidence of common inflammatory mechanisms in CF and COPD
  • Effect of CFTR dysfunction on airway inflammatory/immune responses
  • Role of protease and redox imbalance in CF and COPD inflammatory responses
  • Possible biomarkers of the airway inflammatory process in both diseases
  • Infection/microbiome and inflammatory/immune response in the CF or COPD in lung
  • Potential common therapeutic targets in CF and COPD airway inflammation
  • Therapeutic potential of ion transport modulators in CF and COPD inflammatory process

Articles

  • Special Issue
  • - Volume 2018
  • - Article ID 7280747
  • - Editorial

Airway Inflammatory/Immune Responses in COPD and Cystic Fibrosis

Virginia De Rose | Pierre-Régis Burgel | ... | Catherine Greene
  • Special Issue
  • - Volume 2018
  • - Article ID 1309746
  • - Review Article

Airway Epithelium Dysfunction in Cystic Fibrosis and COPD

Virginia De Rose | Kevin Molloy | ... | Catherine M. Greene
  • Special Issue
  • - Volume 2018
  • - Article ID 7501851
  • - Research Article

Long Noncoding RNAs and mRNA Regulation in Peripheral Blood Mononuclear Cells of Patients with Chronic Obstructive Pulmonary Disease

Xiaoyan Qu | Xiaomin Dang | ... | Ying Chang
  • Special Issue
  • - Volume 2018
  • - Article ID 1601486
  • - Review Article

Towards Targeting the Aryl Hydrocarbon Receptor in Cystic Fibrosis

Matteo Puccetti | Giuseppe Paolicelli | ... | Teresa Zelante
  • Special Issue
  • - Volume 2018
  • - Article ID 1067134
  • - Review Article

The EGFR-ADAM17 Axis in Chronic Obstructive Pulmonary Disease and Cystic Fibrosis Lung Pathology

Marta Stolarczyk | Bob J. Scholte
  • Special Issue
  • - Volume 2017
  • - Article ID 3028082
  • - Research Article

Cigarette Smoke Exposure Inhibits Bacterial Killing via TFEB-Mediated Autophagy Impairment and Resulting Phagocytosis Defect

Garrett Pehote | Manish Bodas | ... | Neeraj Vij
  • Special Issue
  • - Volume 2017
  • - Article ID 5047403
  • - Research Article

Comparison of Oropharyngeal Microbiota from Children with Asthma and Cystic Fibrosis

Sébastien Boutin | Martin Depner | ... | Alexander H. Dalpke
  • Special Issue
  • - Volume 2017
  • - Article ID 6506953
  • - Research Article

Effect of IRAK-M on Airway Inflammation Induced by Cigarette Smoking

Haihong Gong | Tao Liu | ... | Jinming Gao
Mediators of Inflammation
 Journal metrics
Acceptance rate34%
Submission to final decision52 days
Acceptance to publication29 days
CiteScore6.000
Impact Factor3.758
 Submit

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.